Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 32.79
(2.63%)
USD 32.79
(2.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 787.64 Million USD | 34.18% |
| 2022 | 587 Million USD | -27.53% |
| 2021 | 810 Million USD | 11.11% |
| 2020 | 729 Million USD | -35.08% |
| 2019 | 1.12 Billion USD | 87.27% |
| 2018 | 599.67 Million USD | 18.12% |
| 2017 | 507.66 Million USD | 46.46% |
| 2016 | 346.62 Million USD | 22.18% |
| 2015 | 283.7 Million USD | 32.47% |
| 2014 | 214.16 Million USD | 45.41% |
| 2013 | 147.28 Million USD | 44.33% |
| 2012 | 102.04 Million USD | 2.99% |
| 2011 | 99.08 Million USD | -8.65% |
| 2010 | 108.47 Million USD | -10.8% |
| 2009 | 121.6 Million USD | 13.44% |
| 2008 | 107.19 Million USD | 53.96% |
| 2007 | 69.62 Million USD | 183.8% |
| 2006 | 24.53 Million USD | -38.87% |
| 2005 | 40.13 Million USD | -5.84% |
| 2004 | 42.62 Million USD | -14.73% |
| 2003 | 49.99 Million USD | -37.65% |
| 2002 | 80.17 Million USD | 50.51% |
| 2001 | 53.27 Million USD | 43.0% |
| 2000 | 37.25 Million USD | 9.9% |
| 1999 | 33.9 Million USD | -13.52% |
| 1998 | 39.2 Million USD | 20.62% |
| 1997 | 32.5 Million USD | 43.81% |
| 1996 | 22.6 Million USD | 73.85% |
| 1995 | 13 Million USD | 28.71% |
| 1994 | 10.1 Million USD | -16.53% |
| 1993 | 12.1 Million USD | 39.08% |
| 1992 | 8.7 Million USD | 38.1% |
| 1991 | 6.3 Million USD | 215.0% |
| 1990 | 2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 119.49 Million USD | -63.18% |
| 2024 Q2 | 225.25 Million USD | 88.5% |
| 2023 Q3 | 144 Million USD | -23.4% |
| 2023 Q4 | 324.5 Million USD | 125.35% |
| 2023 FY | 787.64 Million USD | 34.18% |
| 2023 Q1 | 131 Million USD | -13.82% |
| 2023 Q2 | 188 Million USD | 43.51% |
| 2022 Q1 | 141.91 Million USD | -67.75% |
| 2022 Q2 | 133.79 Million USD | -5.73% |
| 2022 Q3 | 159.76 Million USD | 19.42% |
| 2022 Q4 | 152 Million USD | -4.86% |
| 2022 FY | 587 Million USD | -27.53% |
| 2021 FY | 810 Million USD | 11.11% |
| 2021 Q1 | 111.6 Million USD | -61.51% |
| 2021 Q2 | 125.75 Million USD | 12.67% |
| 2021 Q4 | 440 Million USD | 230.6% |
| 2021 Q3 | 133.09 Million USD | 5.84% |
| 2020 Q1 | 133.36 Million USD | -73.0% |
| 2020 FY | 729 Million USD | -35.08% |
| 2020 Q2 | 145.53 Million USD | 9.13% |
| 2020 Q3 | 160.07 Million USD | 9.99% |
| 2020 Q4 | 290 Million USD | 81.16% |
| 2019 FY | 1.12 Billion USD | 87.27% |
| 2019 Q1 | 297.21 Million USD | 54.71% |
| 2019 Q3 | 167.89 Million USD | 2.37% |
| 2019 Q2 | 164 Million USD | -44.82% |
| 2019 Q4 | 494 Million USD | 194.24% |
| 2018 Q2 | 117.74 Million USD | -18.47% |
| 2018 Q4 | 192.11 Million USD | 32.13% |
| 2018 FY | 599.67 Million USD | 18.12% |
| 2018 Q3 | 145.39 Million USD | 23.48% |
| 2018 Q1 | 144.41 Million USD | -16.18% |
| 2017 FY | 507.66 Million USD | 46.46% |
| 2017 Q1 | 110.3 Million USD | -31.21% |
| 2017 Q4 | 172.29 Million USD | 42.5% |
| 2017 Q3 | 120.91 Million USD | 16.09% |
| 2017 Q2 | 104.15 Million USD | -5.58% |
| 2016 Q4 | 160.34 Million USD | 44.55% |
| 2016 Q2 | 38.47 Million USD | 4.33% |
| 2016 Q3 | 110.92 Million USD | 188.35% |
| 2016 FY | 346.62 Million USD | 22.18% |
| 2016 Q1 | 36.87 Million USD | -28.5% |
| 2015 Q4 | 51.57 Million USD | 4.99% |
| 2015 Q1 | 62.58 Million USD | -26.25% |
| 2015 Q2 | 120.42 Million USD | 92.43% |
| 2015 Q3 | 49.12 Million USD | -59.21% |
| 2015 FY | 283.7 Million USD | 32.47% |
| 2014 Q2 | 57.07 Million USD | 102.68% |
| 2014 FY | 214.16 Million USD | 45.41% |
| 2014 Q4 | 84.86 Million USD | 92.59% |
| 2014 Q1 | 28.16 Million USD | -33.34% |
| 2014 Q3 | 44.06 Million USD | -22.8% |
| 2013 Q3 | 23.58 Million USD | -38.08% |
| 2013 FY | 147.28 Million USD | 44.33% |
| 2013 Q4 | 42.24 Million USD | 79.13% |
| 2013 Q2 | 38.09 Million USD | -12.15% |
| 2013 Q1 | 43.36 Million USD | 118.19% |
| 2012 Q3 | 11.6 Million USD | -75.49% |
| 2012 Q1 | 23.23 Million USD | -28.29% |
| 2012 Q4 | 19.87 Million USD | 71.3% |
| 2012 FY | 102.04 Million USD | 2.99% |
| 2012 Q2 | 47.34 Million USD | 103.74% |
| 2011 Q4 | 32.4 Million USD | 56.44% |
| 2011 FY | 99.08 Million USD | -8.65% |
| 2011 Q1 | 21.14 Million USD | -19.96% |
| 2011 Q2 | 24.82 Million USD | 17.38% |
| 2011 Q3 | 20.71 Million USD | -16.56% |
| 2010 FY | 108.47 Million USD | -10.8% |
| 2010 Q4 | 26.42 Million USD | -7.7% |
| 2010 Q2 | 23.5 Million USD | -21.46% |
| 2010 Q1 | 29.92 Million USD | -7.24% |
| 2010 Q3 | 28.62 Million USD | 21.79% |
| 2009 FY | 121.6 Million USD | 13.44% |
| 2009 Q3 | 26.77 Million USD | -13.62% |
| 2009 Q2 | 30.99 Million USD | -1.85% |
| 2009 Q4 | 32.26 Million USD | 20.51% |
| 2009 Q1 | 31.57 Million USD | 52.83% |
| 2008 Q2 | 32.96 Million USD | 54.36% |
| 2008 Q4 | 20.66 Million USD | -35.87% |
| 2008 FY | 107.19 Million USD | 53.96% |
| 2008 Q1 | 21.35 Million USD | -13.64% |
| 2008 Q3 | 32.21 Million USD | -2.26% |
| 2007 Q3 | 38.63 Million USD | 913.14% |
| 2007 FY | 69.62 Million USD | 183.8% |
| 2007 Q1 | 2.45 Million USD | -79.49% |
| 2007 Q2 | 3.81 Million USD | 55.63% |
| 2007 Q4 | 24.72 Million USD | -35.99% |
| 2006 FY | 24.53 Million USD | -38.87% |
| 2006 Q4 | 11.94 Million USD | 267.2% |
| 2006 Q3 | 3.25 Million USD | -25.65% |
| 2006 Q2 | 4.37 Million USD | -11.76% |
| 2006 Q1 | 4.95 Million USD | -66.14% |
| 2005 Q3 | 7.45 Million USD | -29.59% |
| 2005 Q4 | 14.64 Million USD | 96.31% |
| 2005 Q2 | 10.59 Million USD | 42.33% |
| 2005 FY | 40.13 Million USD | -5.84% |
| 2005 Q1 | 7.44 Million USD | -34.63% |
| 2004 FY | 42.62 Million USD | -14.73% |
| 2004 Q1 | 12.3 Million USD | 26.85% |
| 2004 Q2 | 9.84 Million USD | -20.0% |
| 2004 Q3 | 9.09 Million USD | -7.62% |
| 2004 Q4 | 11.38 Million USD | 25.21% |
| 2003 Q4 | 9.69 Million USD | -14.12% |
| 2003 Q2 | 15.01 Million USD | 7.41% |
| 2003 FY | 49.99 Million USD | -37.65% |
| 2003 Q1 | 13.98 Million USD | -36.04% |
| 2003 Q3 | 11.29 Million USD | -24.79% |
| 2002 Q1 | 17.95 Million USD | -17.41% |
| 2002 Q4 | 21.85 Million USD | 7.68% |
| 2002 Q3 | 20.3 Million USD | 1.19% |
| 2002 Q2 | 20.06 Million USD | 11.7% |
| 2002 FY | 80.17 Million USD | 50.51% |
| 2001 FY | 53.27 Million USD | 43.0% |
| 2001 Q1 | 4.63 Million USD | -41.62% |
| 2001 Q4 | 21.74 Million USD | 12.64% |
| 2001 Q3 | 19.3 Million USD | 154.27% |
| 2001 Q2 | 7.59 Million USD | 63.87% |
| 2000 Q4 | 7.93 Million USD | -56.59% |
| 2000 Q1 | 4.05 Million USD | -57.33% |
| 2000 Q3 | 18.28 Million USD | 161.7% |
| 2000 Q2 | 6.98 Million USD | 72.3% |
| 2000 FY | 37.25 Million USD | 9.9% |
| 1999 Q3 | 10.6 Million USD | 47.22% |
| 1999 FY | 33.9 Million USD | -13.52% |
| 1999 Q4 | 9.5 Million USD | -10.38% |
| 1999 Q1 | 6.6 Million USD | -13.16% |
| 1999 Q2 | 7.2 Million USD | 9.09% |
| 1998 Q3 | 19.8 Million USD | 241.38% |
| 1998 Q4 | 7.6 Million USD | -61.62% |
| 1998 Q2 | 5.8 Million USD | 0.0% |
| 1998 Q1 | 5.8 Million USD | -38.3% |
| 1998 FY | 39.2 Million USD | 20.62% |
| 1997 FY | 32.5 Million USD | 43.81% |
| 1997 Q2 | 5.8 Million USD | 26.09% |
| 1997 Q3 | 12.6 Million USD | 117.24% |
| 1997 Q1 | 4.6 Million USD | -28.13% |
| 1997 Q4 | 9.4 Million USD | -25.4% |
| 1996 Q4 | 6.4 Million USD | 25.49% |
| 1996 Q1 | 6.4 Million USD | 88.24% |
| 1996 FY | 22.6 Million USD | 73.85% |
| 1996 Q3 | 5.1 Million USD | 8.51% |
| 1996 Q2 | 4.7 Million USD | -26.56% |
| 1995 Q3 | 3.7 Million USD | 12.12% |
| 1995 Q4 | 3.4 Million USD | -8.11% |
| 1995 FY | 13 Million USD | 28.71% |
| 1995 Q2 | 3.3 Million USD | 26.92% |
| 1995 Q1 | 2.6 Million USD | 230.0% |
| 1994 Q2 | 3.1 Million USD | 19.23% |
| 1994 Q3 | 3.2 Million USD | 3.23% |
| 1994 Q4 | -2 Million USD | -162.5% |
| 1994 FY | 10.1 Million USD | -16.53% |
| 1994 Q1 | 2.6 Million USD | -10.34% |
| 1993 Q2 | 3.2 Million USD | 18.52% |
| 1993 Q4 | 2.9 Million USD | -12.12% |
| 1993 FY | 12.1 Million USD | 39.08% |
| 1993 Q1 | 2.7 Million USD | 350.0% |
| 1993 Q3 | 3.3 Million USD | 3.13% |
| 1992 FY | 8.7 Million USD | 38.1% |
| 1992 Q2 | 2.3 Million USD | -8.0% |
| 1992 Q1 | 2.5 Million USD | 212.5% |
| 1992 Q3 | 3.3 Million USD | 43.48% |
| 1992 Q4 | 600 Thousand USD | -81.82% |
| 1991 Q2 | 1.5 Million USD | 0.0% |
| 1991 Q3 | 2 Million USD | 33.33% |
| 1991 Q4 | 800 Thousand USD | -60.0% |
| 1991 FY | 6.3 Million USD | 215.0% |
| 1991 Q1 | 1.5 Million USD | 200.0% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | 500 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | 2 Million USD | 0.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -4871.577% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -22404.2% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2420.551% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -2836.461% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -9087.531% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -3656.424% |
| Imunon, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -239.088% |
| Editas Medicine, Inc. | 78.12 Million USD | -908.214% |
| FibroGen, Inc. | 147.75 Million USD | -433.087% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -66144.491% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 58.262% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 36.651% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -29.649% |
| Verastem, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 8.54 Billion USD | 90.781% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 92.019% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -346.938% |
| Homology Medicines, Inc. | -6.65 Million USD | 11942.535% |
| Nektar Therapeutics | 90.12 Million USD | -773.979% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 83.082% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -577.057% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.467% |
| Illumina, Inc. | 4.5 Billion USD | 82.512% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 98.162% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 94.743% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -519.98% |
| Waters Corporation | 2.95 Billion USD | 73.358% |
| Biogen Inc. | 9.83 Billion USD | 91.992% |
| Evolus, Inc. | 202.08 Million USD | -289.76% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | -2570.261% |
| Geron Corporation | 237 Thousand USD | -332240.506% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 56.919% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -97.229% |
| Myriad Genetics, Inc. | 678.4 Million USD | -16.104% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -2071.322% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 79.208% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 67.442% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 93.995% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 88.473% |
| OPKO Health, Inc. | 863.49 Million USD | 8.784% |
| Exelixis, Inc. | 1.83 Billion USD | 56.964% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -63.285% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -191.074% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 5.017% |
| Blueprint Medicines Corporation | 249.38 Million USD | -215.842% |
| Insmed Incorporated | 305.2 Million USD | -158.069% |
| TG Therapeutics, Inc. | 233.66 Million USD | -237.088% |
| Incyte Corporation | 3.69 Billion USD | 78.687% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 24.936% |